Orexo postpones publication of the Annual Report

Rhea-AI Summary

Orexo AB has announced a postponement of the publication date for its 2022 Annual Report from March 24, 2023, to March 28, 2023. This change is attributed to extended auditing processes related to the European Single Electronic Format (ESEF). In 2022, Orexo reported total net sales of SEK 624 million and had 126 employees. The company is actively involved in the development of pharmaceuticals and digital therapies addressing substance use disorders and mental health, with its leading product ZUBSOLV® marketed mainly in the U.S.

Positive

• Total net sales for 2022 reached SEK 624 million.
• Orexo is focused on addressing unmet needs in substance use disorders and mental health.

Negative

• Postponement of the Annual Report may raise concerns regarding financial transparency.

UPPSALA, Sweden, March 15, 2023 /PRNewswire/ -- Orexo AB (publ), (STO:ORX) (OTCQX:ORXOY), has resolved to postpone the publication of the Annual Report for 2022 to March 28, 2023. The previously announced date for publication was March 24, 2023. The change in date is due to prolonged audit of the financial reporting in the European Single Electronic Format, ESEF.

For further information please contact:

Orexo AB (publ.)

Lena Wange, IR & Communications Director
Tel: +46 (0)18 780 88 00
E-mail: ir@orexo.com 

About Orexo

Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of substance use disorders and mental health. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for treatment of opioid use disorder. Total net sales for 2022 amounted to SEK 624 million and the number of employees was 126. Orexo is listed on the Nasdaq Stockholm Main Market (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.

For more information about Orexo please visit www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn, and YouTube.

The information was submitted for publication at 6 pm CET on March 15, 2023. 

 

View original content:https://www.prnewswire.com/news-releases/orexo-postpones-publication-of-the-annual-report-301773314.html

SOURCE Orexo

FAQ

When will Orexo publish its Annual Report for 2022?

Orexo will publish its Annual Report for 2022 on March 28, 2023.

Why has Orexo postponed the publication of its Annual Report?

The postponement is due to prolonged auditing processes related to the European Single Electronic Format (ESEF).

What were Orexo's total net sales for 2022?

Orexo's total net sales for 2022 amounted to SEK 624 million.

What is Orexo's leading product marketed in the U.S.?

Orexo's leading product marketed in the U.S. is ZUBSOLV®, used for treating opioid use disorder.

What is the stock symbol for Orexo?

The stock symbol for Orexo is ORXOY on the OTCQX.